Pipeline
Endeavor BioMedicines’ Pipeline
Endeavor’s pipeline is currently focused on continued demonstration of therapeutic potential in fibrotic lung disease as well as human proof-of-concept data in human epidermal growth factor 3 (HER3)-positive tumors.
ENV-101
IPF
Hedgehog Pathway Inhibitor
ENV-501
Oncology
HER3-Targeting ADC
Phase 2a Clinical Trial Results
At the American Thoracic Society 2024 International Conference, Endeavor BioMedicines announced results from a completed Phase 2a clinical trial that demonstrate our lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis (IPF).
